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 Liver transplantation has been established as the treatment of choice for most 
patients with end-stage irreversible, acute and chronic liver disease and is 
performed on a routine basis in most major centres throughout the world, 1 with 




 The first attempt at liver transplantation was performed in dogs in 1955 where the 
auxiliary liver was engrafted heterotopically in either the pelvis or right 
paravertebral gutter.  The portal vein was anastomosed to the inferior vena cava 
and the hepatic artery to the aorta or iliac artery.3, 4 There was no 
immunosuppression. 
 Human liver transplantation 
 Thomas Starzl in 1963 first attempted human liver transplantation in a 3-year old 
boy with biliary atre ia.  The patient died of severe blood loss.5 Initial results with 
human liver transplantation remained poor with survival rates between 0-23 days. 
The management of the haemodynamic and metabolic problems by 
anaesthesiologists who specialize in liver transplantation, the use of modern blood 
component and coagulation factor replacement therapy, and improved surgical 
methods to control operative bleeding have improved the outcome of liver 
transplantation.6, 7 
The massive blood loss that routinely characterized earlier operations to a large 
extent has been reversed, and liver transplantation today is associated with 
minimal blood loss. The introduction of the venovenous bypass has led to the 
development of new transplant programs since the haemodynamic crisis during 












Other factors which led to the improvement in the results included the 
improvement in the knowledge of liver anatomy, improved surgical techniques, 
use of more potent immunosuppressant drugs, and the management of the 
haemodynamic problems. There has also been improved histological monitoring 
for early signs of graft damage, better post operative monitoring and the 
introduction of a close working transplant team. 
At present the reported 1 and 3 years survival rates in USA are 77% and 68% 
respectively and 73% and 65% in Europe.9 
Deaths within the first 6 months are caused by primary non-function of the 
allograft, hepatic artery thrombosis, infection, multi-organ failure or allograft 
rejection. Late death is commonly caused by atherosclerotic disease or 
malignancy. 
C) 
The indications for liver transplantation are listed in Table1.1 
The list of indications continues to expand, so that liver transplantation should 
now be considered in nearly all patients with advanced chronic liver disease and 
fulminant hepatic failure. 
Liver diseases for which liver transplantation has been performed can be divided 
generally into 4 groups. 
INDICATIONS FOR LIVER TRANSPLANTATION 
• Advanced irreversible chronic liver failure 
• Fulminant hepatic failure 
• Hepatic malignancies 
• Inherited metabolic disorders 
Some metabolic liver disease eg antitrypsin deficiency result in liver damage and 
the patients are transplanted for liver failure. 
Other inherited disorders, such as type II hypercholesterolinaemia, the enzyme 
defect resides in the hepatocytes, but other end organs are damaged. In primary 











results in damage of the renal allograft; the enzyme defect has to be reversed by a 
liver transplant. 
The chronic liver diseases consist of the hepatocellular diseases such as auto-
immune diseases, cryptogenic cirrhosis, and the cholestatic liver diseases, such as 
primary sclerosing cholangitis. 
Liver transplantation for hepatic malignancies has been performed with better 
prognosis in patients with small tumours (<5cm) without vascular invasion. 
One of the major problems in the management of a patient with liver disease is to 
determine the optimal timing of the liver transplant procedures. 
TABLE 1.1:  INDICATIONS FOR LIVER TRANSPLANTATION 
1 Chronic liver disease 
a) Primary biliary cirrhosis 
b) Primary sclerosing cholangitis 
c) Chronic drug induced cholestasis and biliary cirrhosis 
d) Chronic virus induced liver disease 
e) Chronic drug induced liver disease 
f) Alcoholic liver disease 
g) Idiopathic autoimmune chronic active hepatitis and cirrhosis 
h) Wilson disease  
i) Congenital hepatic fibrosis 
j) Budd chiari syndrome 
k) Venous occlusive disease  
2 Fulminant hepatic failure 
a) Viral hepatitis 
b) Drug induced liver disease 
c) Quinidine 
d) Wilson disease 
3 Hepatic malignancies 
a) Hepatocellular carcinoma 
4 Metabolic liver disease 
a) Hemophilia A 
b) Type ii hypercholesterolaemia 
c) Primary hyperoxaluria type1 












 The following parameters are used to decide when the transplant should be done 
in a patient with chronic liver disease. 
 The most common clinical indications are: 
TIMING OF LIVER TRANSPLANTATION 
• Intractable ascites 
• Severe encephalopathy 
• Variceal haemorrhage 
• Diminishing quality of life 
Complications of severe hepatic dysfunctions, like severe ascites, variceal 
haemorrhage, hepatorenal syndrome, recurrent spontaneous bacterial peritonitis, 
severe encephalopathy and sustained severe jaundice are late manifestations of 
liver disease and represent an urgent consideration for liver transplantation 
Recently, the model for end-stage liver disease (MELD) score was introduced for 
recipient selection in the United States of America with the focus on maximizing 
the utility of organ allocation and transplant benefit. 
The adoption of this scoring system for liver allocation has been successful in 
implementing a system based on medical urgency rather than waiting time.  It has 
reduced the mortality of patients on the waiting list significantly.  However, 
despite this shift to sicker patients, there has been no difference in one year 
patient and graft survival after the implementation of MELD.10, 11 It is a good 
predictor of pre-transplant survival but a weak predictor of post-transplant 
survival.11 
 


























The contraindications to liver transplantation are listed in Table 1.3 
At present, the absolute contraindications to liver transplantation are extrahepatic 
malignancy, septicaemia and severe underlying cardiopulmonary or systemic 
disease.12,13  Interestingly, human immuno deficiency virus (HIV) infection is no 
longer an absolute contraindication to liver transplantation provided strict criteria 
for disease stage are fulfilled.  Early results of liver transplantation in HIV-
positive patients are encouraging.14, 15 
 Relative contraindications include; prior extensive abdominal surgery, portal vein 
thrombosis, HBsAg and HBeAg positivity, and hepatoma greater than 5cm.12 
 
 
CONTRAINDICATIONS TO LIVER TRANSPLANTATION 
1. Acute liver failure 
a. Serum bilirubin>10-20mg/dl and increasing 
b. Prothrombin time(PT) >10seconds above normal and increasing 
c. Progressive hepatic encephalopathy(coma) 
2. Chronic liver disease. 
a. Cholestatic liver disease 
i. Bilirubin>10-15mg/dl 
ii. Intractable pruritus 
iii. Malnutrtion 
iv. Recurrent cholangitis 
b. Hepatocellular liver disease 
i. Serum albumin <2.5gm/dl 
ii. Hepatic encephalopathy 
iii. Prothrombin time >5seconds above control values and 
increasing 
c. Factors common to both types of liver disease 
i. Portal hypertension with bleeding from oesophageal varices 
ii. Intractable ascites 
iii. Recurrent spontaneous bacterial peritonitis 
iv. Hepatorenal syndrome 
v. Recurrent episodes of biliary sepsis 












TABLE 1.3:  CONTRAINDICATIONS TO LIVER TRANSPLANTATION 
1. Absolute contraindications 
a. Active sepsis outside the hepatobiliary tree 
b. Malignancy outside the liver 
c. Advanced cardiopulmonary disease 
d. Acquired Immune Deficiency Syndrome (AIDS) 
2. Relative contraindications 
a. Portal vein thrombosis 
b. Cholangiocarcinoma 
c. Age greater than 60 years 
d. HBsAg and HBeAg positivity 













Technical considerations for living donor liver transplantation (LDLT) are total 
hepatectomy with caval preservation, and to achieve as much length on the donor 
vessels as safely as possible.  The recipient explant can be performed without 
venovenous bypass or portocaval decompression.16 
The complete transplant procedure is composed of 4 main stages: 
SURGICAL TECHNIQUE 
• Donor surgery 
• Recipient surgery 
• Implantation of the graft 
• Haemostasis and bile duct reconstruction 
 
i) Donor surgery 
This could either be (1) Right lobectomy (2) Left lobectomy or (3) Left 
lateral segmentectomy. For the right lobectomy, the right lobe is mobilised 
with transection of short hepatic veins. Those along the left margin of the 
hepatic inferior vena cava are left intact. 
The vessels are isolated by dissection of the hepatic hilum. The right 
portal branch and right hepatic artery are clamped for a short time to 
produce the discoloration needed for parenchymal division. Transection 
lines are then made by electrocautery on the surface of the liver just to the 
right of the discoloration line. 
Parenchymal transection of the liver is performed by ultrasonic dissection 
without interruption of the inflow to the liver. The right hepatic duct is 
transected at its bifurcation prior to parenchymal transection. Perfusion of 
the graft is performed through the portal vein and hepatic artery using 
University of Winsconsin solution. 
ii) Recipient surgery 
Adequate exposure is usually achieved by a bilateral subcostal incision, 











recipient hepatectomy usually represents the most difficult stage of the 
entire liver transplant procedure. 
It may be difficult to dissect the structures of the hepatic hilum 
individually because of prior surgery or because of the massive formation 
of varices.  Total hepatectomy is undertaken with preservation of the 
inferior vena cava, with or without veno-venous bypass. The hepatic 
artery, portal vein, suprahepatic and infrahepatic vena cava are clamped. 
The hepatic artery and portal vein are divided and the liver excised with 
the vena cava left intact. The stump of the middle and left hepatic veins 
are closed with a running suture. 
iii) Veno-venous bypass 
The most critical period of the recipient operation is the anhepatic phase, 
when the native liver has been removed and the inferior vena cava and 
portal veins have been occluded. This obligatory clamping of the 
splanchnic and infrahepatic venous system results in a massive 
sequestration of blood volume in the mesenteric venous circulation and the 
circulation of the lower body. Sequelae include severe oedema of the 
whole gastrointestinal tract, renal venous hypertension and an increase in 
bleeding from the thin walled venous collaterals. Other complications 
include volume overload, haemodynamic instability, cardiac arrhythmias 
and arrest on reperfusion, due to the accumulation of potassium and other 
toxic substances in the stagnant venous blood. 
These problems were overcome by the introduction of the pump-driven 
veno-venous bypass system (between the left femoral/ external iliac and 
left axillary vein), without systemic heparinization, during the anhepatic 
phase of the adult recipient operation. This resulted in a significant 
reduction in morbidity and mortality.17 It also made liver transplantation 
an option in patients, previously assessed as too unstable to qualify for the 
procedure. Early placement of the veno-venous bypass greatly facilitates 
the mobilization of the liver from the hepatic fossa and the dissection of 
the vena cava. Appropriate vena caval cuffs and sufficient portal vein 












Veno-venous bypass is used selectively rather than routinely nowadays. 
iv) Graft implantation 
 After adequate haemostasis of the liver bed has been assured, the vena 
cava is prepared. It is much easier to deal with small leaks at this stage, 
rather than at the moment of revascularization. 
After the donor liver is positioned in the recipient hepatic bed, the vena 
caval anastomosis is performed with polypropylene sutures. Prior to 
completion of the anterior side of the suture line, the liver is flushed with a 
minimum of 250ml of a “flush out” solution to wash out the high-
potassium containing preservation solution and the air entrapped inside the 
liver. 
The portal veno-venous bypass cannula is then removed and the portal 
vein is trimmed to the appropriate length. The portal venous anastomosis 
is then performed, and the portal, infrahepatic and suprahepatic vascular 
clamps removed, and the liver revascularised. After controlling major 
leaks with interrupted sutures, the veno-venous bypass is interrupted and 
the remaining cannulae removed. An “expansion” or “growth factor” is 
used to prevent suture line stenosis, especially for the portal vein and 
hepatic artery.18  The donor hepatic artery is anastomosed to the recipient 
hepatic artery.  Bile duct anastomosis is principally duct-to-duct 
choledocho-choledochostomy unless there is a specific indication for a 
biloenteric approach. e.g. Primary sclerosing cholangitis (PSC). 
G) 
Improvements that ultimately provided better survival rates following liver 
transplantation included the use of better preservation solutions from the original 
saline to Collins solutions and later of Wisconsin (gold standard) solutions, which 
extended the preservation time from 6 to 24 hours. The newer preservation 
solutions, including HTK and Celsior, have been shown to be equivalent to 
Wisconsin solution. 
PRESERVATION SOLUTION 
• Eurocollins Solution 











• HTK Solutions 
• Celsior Solution 
i) 
Originally Eurocollins was used as the preservation solution fluid in liver 
transplantation.19, 20 With this solution, the liver could be stored for up to 
six hours.  This covered major logistical problems in that the donor and 
recipient operations had to be carefully co-ordinated. 
Eurocollins Solution 
ii) 
 Folkert Belzer developed the University of Wisconsin (UW) solution. This 
solution was first used to preserve the canine pancreas for 72 hours.21 
subsequently; successful storage of the canine liver for 24 and 48 hours in 
experimental liver transplantation was reported.22 This was followed by 
the report in 1988 of the use of UW solution in human liver 
transplantation.  Tolerance of cold ischaemia was significantly improved 
from 8 hours or less to over 20 hours with Collins solution.23 The 12 
constituents in UW solution were all added to counterbalance specific 
metabolic processes thought to be responsible for preservation injury. The 
compositions of University of Wisconsin solution are listed in table 1.4 



























 The most important constituents of UW solution are lactobionate and 
raffinose as impermeants to suppress hypothermia induced tissue 
swelling.23 Lactobionate is a large sized organic anion, which by nature of 
its size and negative charge is impermeable to most tissue membranes. 
Raffinose, a trisaccharide, and hydroxyl ethyl starch, were both added for 
additional osmotic support and to prevent expansion of extracellular space. 
The phosphate buffer was added to the solution to prevent tissue acidosis 
from anaerobic metabolism by the ischaemic cells. 
 Adenosine and phosphate were added as precursors for ATP-production as 
well as to support energy utilizing reactions.24 Allopurinol and 
gluthathione were added to prevent toxic oxygen radical related damage. 
Recently, some modifications have been made. The potassium salts have 
been replaced successfully by sodium salts. Hydroxyl ethyl starch has 
been omitted without negatively influencing the preservation injury.25, 26 
Despite numerous possible modifications, UW solution remains currently 
the “gold standard” cold preservation solution, with preservation time 
from 18-24 hours.27, 28, 29 
 Component     Amount 
 K-lactobionate     100mM 
 KH2PO4      25Mm 
 MgSO4      5Mm 
 Raffinose     30Mm 
 Adenosine     5Mm 
 Gluthathione     3Mm 
 Allopurinol     1Mm 
 Dexamethasone     16mg 
 Regular insulin     40u/l 
 PenicillinG     200,000u/l 
 Hydroxyl ethyl starch    50g/l 
 Osmolarity     320mOsm/l 











The newer preservation solutions, including HTK and Celsior, have also 
been shown to be equivalent to Wisconsin solution. 
iii) 
Bretschneider developed this solution with a goal of protecting the 
myocardium during cardioplegic period.30 The composition of 
Bretschneider solution are listed in table 1.5 
HTK (Bretschneider) solution  
TABLE 1.5
 
: COMPOSITION OF BRETSCHNEIDER HTK4 SOLUTION 
Histidine was used as a buffering agent. Ketoglutarate and tryptophane 
were added to deliver energy. These substances are able to produce ATP, 
while inhibiting gl colysis and reducing lactate production and tissue 
acidosis. 
Potassium was added to achieve cardiac arrest, while magnesium was 
added to reduce calcium efflux and stabilize ionic membrane status. 
Mannitol was chosen as an agent to increase the osmotic gradient and to 
prevent tissue oedema. 
Since this solution is based on its substantial buffering capacity, high 
volume flush-outs are used allowing equilibration across the cell 
membrane.31 
This solution was successfully used in kidney transplantation and it has 
also been used in liver transplantation. Several European centres have 
introduced HTK solution in their liver transplantation program. 
 
 Component    Amount 
 Histidine    180mM 
 Histidine-Hcl    18mM 
 K-ketoglutarate    1mM 
 Tryptophane    2mM 
 Potassium    9Mm 
 Sodium    15Mm 
 Magnesium    4mM 
 Mannitol    30mM 
 Osmolarity    300mOsm/l 













Celsior was introduced as a new cardioplegic solution, with the aim of 
preventing free radical injury. This remains an important cause of early 
graft dysfunction. The composition of Celsior solution are listed in table 
1.6 
The major feature of Celsior solution is the presence of three anti-
oxidants, reduced glutathione, mannitol and histidine.32, 33, 34 Anti-oxidant 
effects are provided by mannitol and histidine because of their capacity to 
scavenge hydroxyl radicals.33 






:  COMPOSITION OF CELSIOR SOLUTION  
 Component    Amount 
 Mannitol  60mM 
 Lactobionate  80mM 
 Glutamic acid  20mM 
 Histidine  30Mm 
 Reduced glutathione 3mM 
 Potassium  15mM 
 Sodium  100mM 
 Magnesium  13mM 
 Calcium  0.25mM 
 Chloride  41.5mM 
 pH (at 20C)  7.3 













Ringers lactate is suitable because of its similarity to the extracellular 
fluid. Several studies have shown that the use of warm ringers lactate flush 
has an advantage over a cold rinse.35, 36 The use of 4% serum albumin as a 
rinse solution has been shown to compare favourably with the use of 
ringers lactate solution.37 
Flush out solutions 
vi) 
This solution was developed with the aim of minimizing reperfusion 
injury and improving graft survival.38 It consists of 10 empirical 
components, including adenosine, nisodipine, desferrioxamine and 
fructose. The most essential component is adenosine, 37 which inhibits 
platelets aggregation, 39 improving microcirculation and conversion to 
ATP. This improves survival. 
Clinical evidence has demonstrated that Carolina rinse solution is more 
effective in reducing cholestatic injury than in decreasing hepatocellular 
damage.40 There are indications that this solution improves graft function 
and microcirculation, but its exact role in human liver transplantation is 
not yet known.41 
Carolina rinse solution 
H) 
The development of the field of immunosuppression was critically important in 
liver transplantation. In 1944, Medawar showed that graft rejection is an 
immunological event that has both specificity and memory.42, 43 
Immunosuppressive regimens are required to control the allogenic response in 
clinical liver transplantation; however they may lead to severe complications such 
as cardiovascular disease and infectious diseases. 
In the precyclosporin era, where corticosteroids and azathioprine were used as 
immunosuppressants, the result was suboptimal. One year survival was 30%. 
IMMUNOSUPPRESSION 













 Calcineurin inhibitors 
 Antibody inductors 
 Antibiotics 
i) 
In the early days of liver transplantation, corticosteroids were the main 
immunosuppressive agent. Steroids remain the most frequently used 
immunosuppressive drug in conjuction with calcineurin inhibitors. 
The mode of action of corticosteroid is non-specific and includes blocking 
T-cell derived and antigen presenting cell derived cytokine expression e.g. 
Interleukins 1-3 and 6.44 
Steroids are used both as treatment of acute rejection, and in maintenance 
therapy. 




The first antimetabolite used in liver transplant was Azathioprine which is 
an imidazolyl derivative of mercaptopurine. Its mode of action is by 
inhibiting the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid 
(RNA) and proteins, and inhibits the proliferation of lymphocytes. 
The most recent additions to the antimetabolite arena are Mycophenolate 
mofetil (MMF) and Mycophenolic acid (MPA) .45 
They both inhibit the de-novo purine nucleotide synthesis. Side effects 
include neutropenia and diarrhoea.46 
Antimetabolites 
iii) 
The calcineurin inhibitors remain the major component of most 
immunossuppression protocols and include: 
 Cyclsporin A (CyA) 
 Tacrolimus (TAC) 











Calne and colleagues in 1978 and 1979 first described cyclosporine A as 
an immunosuppressant with increased survival rate of liver transplant 
recipient from 45% to 70%.47-51 
Cyclosporine A causes selective suppression of cell mediated immunity 
via inhibition of T-cell activation. It is metabolised in the liver via 
cytochrome P450-3A pathway. 
Side effects include nephrotoxicity, hypertension, and gingival 
hyperplasia.52 
In 1984 Tacrolimus was discovered in Japan. It is 100 times more potent 
than CyA. It exerts its action by binding to FK binding protein which 
inhibits calcineurin. Side effects are similar to CyA. Including, 
nephrotoxicity, neurotoxicity and hyperkalaemia.53 
Moreover, a multicenter trial has shown that liver transplant patients 
receiving TAC based immunosuppressant compared to CyA have a lower 
rate of rejection within the first year.54 
iv) 
Anti-lymphocyte antibodies has been used both as part of induction 
therapy, as well as in the treatment of steroid resistant acute rejection. 
The therapy can be seen as depleting or receptor modulating or both. 
The antibodies used in liver transplantation may be monoclonal or 
polyclonal. 
   Polyclonal antibodies 
 These are gamma globulin fractions from animals inoculated with 
human lymphocytes, thymocytes or cultured lymphoblast. They 
causes depletion of T-cells by apoptosis, antibody mediated 
cytolysis and internalization of the cell surface receptors. Side 
effects include tachycardia, chills, gastro-intestinal distubances, 












   Monoclonal antibodies 
 Monoclonal anti T-cell antibodies e.g. Muromonab-CD3 (OKT3) 
are murine derived antibody directed to a specific portion of T-
cells. 
 The mode of action is by binding to the CD3 antigen on the surface 
of T-lymphocytes resulting in rapid fall in number of mature 
lymphocytes.OKT3 was first used in liver transplantation in 1987 
for prophylaxis against acute cellular rejection and later to reduce 
CNI exposure and treatment of steroid resistant rejection.46, 55 Side 
effect includes; pyrexia, chills, dyspnoea, chest pain to severe life 
threatening pulmonary oedema. 
IL-2 receptor antibodies e.g. Basiliximab, Daclizumab. They 
bind to the IL-2R chain. Immunosuppression is achieved by 
competitive antagonism of IL-2 induced T-cell proliferation. Side 
effects are mild gastro-intestinal disturbances.46 
v) 
Rapamycin is a macrolide antibiotic with immunosuppressive, anti-tumour 
and anti-fungal properties. It blocks the response of T and B cell activation 
by cytokines which prevents cell-cycle progression and proliferation by 
binding to the immunophillin FKB12. Side effects include: Leukopenia 
and oral ulcerations. 
Most liver transplant centres use triple-drug regimen (prednisone, either 
cyclosporine or tacrolimus, and azathioprine or MMF). Some centres use 
induction immunosuppression with antilymphocyte globulin such as 
OKT3 (muromonab-CD3, orthodone, orthopharmaceuticals Ravitan, NJ) 
or Atgam (antilymphocyte globulin UpJohn Co.Kalamazoo, Michigan). 
Antilymphocyte induction is used to avoid the potential nephrotoxicity of 
either cyclosporine or tacrolimus. 






















RESULTS OF IMMUNOSUPPRESSION 
The introduction of immunosuppression in liver transplantation has led to 
improvement in patient and graft survival.  One year and 5-year survival ranges 
between 85% and 75% respectively.2 
Year Agent 
1962 Azathioprine. 
1963 Azathioprine plus corticosteroid 
1966 Polyclonal antibodies; antilymphocyte globulin 
1970 Cyclophosphamide substituted for azathioprine 
1978 Cyclosporine use in humans 
1980 Cyclosporine plus corticosteroids 
1981 Development of monoclonal antibodies 
1989 Tacrolimus plus corticosteroid 













STRATEGIES TO IMPROVE DONOR SUPPLY 
Unfortunately, liver transplantation has become a victim of its own success in that 
the supply of donor organs has not been able to keep up with the demand.  The 
majority of donors for liver transplantation are brain-dead cadaver donors 
following either a severe head injury, or a massive intracranial haemorrhage.  The 
numbers of organ donors have remained relatively stable with only minor 
increases in retrieval rates in recent years, in spite of many efforts to increase 
organ donation. This has led to an increase in the number of patients on the liver 
transplantation waiting list, and an increase in the number of deaths on the waiting 
list. 
CRITICAL SHORTAGE OF DONOR ORGANS 
B) 
1. Reduced sized adult liver transplantation 
STRATEGIES TO IMPROVE DONOR SUPPLY 
2. Split liver transplants 
3. Living donor liver transplant 
 The critical shortage of donor livers for transplantation has been addressed in 
several ways, including the use of reduced size adult livers for paediatric 
recipients, the use of split liver transplants, and more recently, the use of living 
donor liver transplants.56 The latter strategies have been the result of a better 
understanding of the anatomy of the liver and knowledge of the latent capacity of 
the liver to undergo regeneration after partial hepatectomy. 
 
i) 
The critical shortage of donor livers was a particular problem in paediatric 
population. This problem has to a large extent been overcome by the use 
of reduced size adult livers. 











The left lateral segments, the left lobe or the right lobe of the liver are 
transplanted. Patient and graft survival are similar to intact liver 
transplantation.57 
Success with reduced size liver transplantation led to the development of 
split liver technique, in which one liver is split into two functioning units 
and used for two recipients.58 This technique is far more challenging since 
extensive reconstruction of the segmental vessels and biliary system are 
required. The initial poor results were due primarily to the selection of 
poor-risk recipients.59 It is now performed with good result in selected 
experienced centres.60, 61 
ii) 
Heterotopic (auxiliary) liver transplantation has been proposed for 
fulminant hepatic failure with the ultimate goal to bridge the patient to 
allow recovery of the native liver.62 It has also been performed for end 
stage chronic liver disease.63 
A recent modification involves partial resection of the native recipient 
liver and implantation of part of the donor liver in the orthotopic position 
i.e. auxilary partial orthotopic liver transplantation (APOLT). 
The main advantage of this technique is that recovery of the native liver 
function eliminates the need for chronic immunosuppression. The 
disadvantage includes a higher number of vascular complications. 
Auxiliary liver transplantation 
iii) 
Living donor liver transplantation (LDLT) was first performed in children 
with acute liver failure and is now routinely performed in most major 
centres with a decrease in the waiting list for children, the group in which 
the gap between demand and supply of livers for transplantation was most 
acute.64 
The experience gained in paediatric living related liver transplantation and 
the encouraging results, led to the development of adult to adult LDLT 
which provides several advantages to the recipient when compared to the 
cadaver donor.  Advantages of LDLT over cadaver donor include: 











1) The transplant procedure can be scheduled electively. 
2) Cadaveric donor factors, such as hypotensive episodes and use of 
pressor support are avoided with LDLT because the donor is 
always healthy and haemodynamically stable with good liver 
functions. 
3) Total ischaemic time is minimized, resulting in excellent initial 
function of the graft and more rapid recovery of the recipient. 
In some centres like Japan, where brain death laws were not established, 
most orthotopic liver transplants were from living related donors. 
Unfortunately, one third of potential living related donors are unsuitable, 
either because of liver problems or due to underlying medical conditions. 
 The risk to the donor is low. The one year survival rates for the recipients 
are excellent and approach 100% in elective cases, while results from 




Donor safety is of prime importance in LDLT because the 
procedure subjects a healthy person to a major surgery and 
potential morbidity and mortality.65 
1) Donors must accept the risk of surgery and should agree to 
donation voluntarily and without coercion. 
2) Donors need to be evaluated psychologically. 
3) Blood groups need to be determined.  The majority of 
donor/recipient combinations have been A.B.O compatible, 
but not exclusively. 
4) Meeting with the potential donor, recipient and their 
immediate family members is extremely important.  In this 











transplantation, including operative and post-operative 
complications of both the donor and recipient procedures. 
5) The need for long-term follow-up of donors and recipients 
especially for donors of right (R) lobe grafts. 
6) Associated co-morbidity of donors needs to be discussed 
e.g., obesity is a contra-indication along with assisted risk 
of hypertension, diabetes and ischaemic heart disease. 
7) Hepatitis B (Hep B) surface antigen positive donors are 
excluded from donation. 
   Imaging/Radiology 
Pre-operative imaging is important for donor hepatectomy in order 
to ensure that remnant segments are left with their inflow (arterial 
and portal) and drainage systems intact (veins and bile ducts).  This 
is important when the remnant liver is small. 
Moreover, anomalous hepatic anatomy, particularly arterial, is 
common and can be a contra-indication to donation. 
The investigation of choice to assess the donor liver is a 
Doppler/ultrasound to evaluate any gross pathology or portal vein 
thrombosis. 
Newer generation multi-sliced CT and three-dimensional 
reconstruction are used for volumetric analysis and to identify 
important anatomic variants.66, 67 
Magnetic resonant imaging (MRI) also provides acceptable high 
resolution imaging without the added risk of radiation and contrast 
exposure as compared to CT.68-70 
Both modalities can detail portal, arterial and biliary roadmaps as 
one-off procedures. 
Angiography is another modality which is not routinely performed, 
but some centres still prefer conventional angiography for vascular 













There is consensus on minimum graft size requirements in living 
donor liver transplantation.  A graft to recipient weight ration 
(GRWR) of more than 0.8 is suggested to provide enough liver 
volume for the recipient. 
The term “small for size syndrome” is used to refer to the clinical 
consequences of using a graft that is too small.  In order not to 
have small for size syndrome, besides calculating the graft to 
recipient weight ratio GRWR, the recipient’s medical condition 
(Child’s classification.), the recipients portal flow dynamics, and 
segmental outflow problems must be taken into account. 
Determining the correct size of the graft is vital.  Adult 
donors/recipients have to be well matched in terms of body mass 
index (BMI).  In most cases when the body weight of the recipient 
is 30% more than the donor, it is unlikely that the donor operation 
will yield a graft of sufficient size and leave an adequate 
remnant.72 
With respect to living donor liver transplantation (LDLT) different 
formulae have been devised for guidance.  To predict a safe 
remnant volume the graft is expressed as a percentage of the 
standard liver volume (SLV).73 It is generally agreed upon that 
between 30%-40% of the SLV is sufficiently safe. 
Grafts can be classified according to whether they are segmental 
(eg segment III) or contain multiple segments.  The most common 
types of grafts are left lateral segmental, left lobe or right lobe, 
with or without the middle hepatic vein.74  In general, left lateral 
grafts are for paediatric recipients, right lobe grafts for 30-60 kg 
recipients, and right extended lobe grafts for recipients >60kg. 
Techniques to reduce small for size syndrome include portal flow 
reduction by shunting.  Graft/recipient body weight ratio (GRWR) 












then a GRWR of >0.85% will be required in order to avoid small 
for size syndrome.75 
 
                                                                                Graft volume 














FIGURE 2.: THE LIVER EIGHT SEGMENT DIVISIONS 
 
 
Left lateral segment includes segment 2 and 3. 
Left lobe includes segment 2, 3 and 4. 

















Liver regeneration is a fascinating process that makes living related liver 
transplantation feasible. It is an important determinant of the success rate, 
especially for recipients of partial liver transplants.  
INTRODUCTION 
B) 
The ancient Greeks were the first to recognise liver regeneration in the myth of 
Prometheus who was condemned to having a portion of his liver eaten by the 
eagles for stealing the secrets of fire from the Gods of Olympus - only to find out 
that the liver regenerates overnight, thus providing the eagle with eternal food and 
Prometheus with eternal torture. 
Liver regeneration has been studied in both animals and humans. In 1931 Higgins 
and Anderson defined the characteristics of hepatic regeneration after 2/3rd partial 
hepatectomy in rats.76 The qualitative account of the changes in rat liver weight 
following this procedure was described. The morphological, chemical and 
histochemical features following standard 2/3rd partial hepatectomy in the rat are 
well established. It was observed that within 18-24 hours post partial 2/3rd 
hepatectomy, there is restorative cell growth within the liver which is 
characterised by an increase in DNA synthesis and liver weight. The residual 
lobes almost double in size within 48 hours, and approach the original liver 
weight by seven days. Macroscopically, the regenerating liver appears pale and 
swollen during the first day due to the extensive temporary infiltrations of neutral 
fat. Microscopically, there are changes in the parenchymal cells at the periphery 
of the hepatic lobule which progresses towards the centre. Mitotic activity of 















 The liver has a latent capacity to undergo regeneration after injury or partial 
hepatectomy.77 A number of mechanisms participate in the hepatic injury that 
occurs during and following liver transplantation. A variety of genes, cytokines, 
growth factors and cells are involved in liver regeneration.78 The exact 
mechanism of regeneration and the interaction between cells and cytokines are 
not fully understood. 
There seems to exist a sequence of stages that result in liver regeneration, while at 
the same time inhibitors control the size of the regenerated liver. Precise factors 
which initiate and terminate the regenerative response remain unresolved.79, 80 
Previous studies have suggested that the regenerating liver itself may be a source 
of hepatotrophic factors.81, 82 A liver cytosol prepared from regenerating liver 
after partial hepatectomy was able to potentiate the regenerative response, 
whereas cytosol from normal liver did not.83 
Several of the immunosuppressive drugs used after liver transplantation has been 
shown to potentiate the regenerative response after partial hepatectomy. Both 
cyclosporine and tacrolimus are thought to be hepatotrophic.84-87 
 
CONTROL OF LIVER REGENERATION 
D) 
Liver regeneration in the recipient and in the donor after living donor liver 
transplantation has been studied to a limited extent.  Various techniques which 
have been used to measure organ volume includes ultrasonography, magnetic 
resonance imaging, nuclear scintigraphy, conventional computed tomography CT, 
cine CT, and helical CT.80, 88 
Computer tomography (CT) has been the standard method of determining liver 
mass.  MRI has technical advantages over CT, particularly in liver donors and 
transplant recipients. This technique avoids potential complication associated with 
the use of traditional intravenous contrast agents and exposure to ionizing 
radiation, and can therefore be performed repeatedly with minimal risk to the 
patient. 











Several studies have shown that the donor liver takes longer to restore liver mass 
than the transplanted liver in the recipient.89, 90 In fact; liver mass in the donor has 
still not been restored to pre-operative size by one year after surgery. 
Several factors may be responsible for this discrepancy in the regenerative 
response between the recipient and the donor.  Firstly, the recipient has high 
levels of circulating hepatotrophic factors because of the liver disease.  Secondly, 
the recipient also receives cyclosporine, which is known to be hepatotrophic in 
the post transplant period.84-87 In contrast; the donor because of the normal liver 
preoperatively does not have any circulating hepatotrophic factors, and secondly 

































AIM OF THE STUDY  
 
 
Living donor liver transplantation (LDLT) is now well established and performed 
on a routine basis in many major centres around the world. LDLT is feasible 
because of the capacity of both the remnant donor liver and the transplanted 
partial liver to undergo liver regeneration. However it has been demonstrated that 
liver regeneration in the recipient is rapid, whereas restoration of liver mass in the 
donor is delayed.89, 90 
This discrepancy in the rate of regeneration could be due to the presence of 




The aims of the studies were to determine if hepatotrophic factors and 
immunosuppression (Cyclosporine) could modify the restoration of the liver mass 
after partial hepatectomy in rats. 















MATERIALS & METHODS  
 
This study was approved by the Faculty Animal Ethics Committee of the 
University of Cape Town. Adult male Long Evans rats weighing 200-250 grams 
were maintained under standard laboratory conditions and allowed ad libitum 
access to a standard rat pellet diet and water.  Following an equilibration period, 
the rats were subjected to either standard 2/3rd partial hepatectomy (PH) or sham 
operation (SH).  All surgical procedures were performed under light ether 
anaesthesia between 08h00 and 11h00.  The animals were randomly allocated to 
the following treatment groups: 
ANIMALS 
• Group 1 partial hepatectomy (PH) (n=30)  
• Group 2 partial hepatectomy + cyclosporine + liver cytosol (PH + 
Cy + C) (n=30) 
• Group 3 sham operation (SH) (n=30) 




A 2/3rd standard partial hepatectomy was performed via a midline laparotomy 
extending from the xiphisternum posteriorly for approximately 2 centimetres. The 
liver was extruded through the incision, and involved removal of the left lateral 
and middle lobes of the liver. The right lateral and caudate lobes were left intact. 
The abdominal wall and integuments were closed separately by continuous 
sutures.  Sham operation consisted of a midline laparotomy and gentle 













A separate group of 5 animals were subjected to 2/3rd partial hepatectomy and 
sacrificed 24 hours post-operatively.  The remnant livers were removed, 
homogenized in 0,9 % normal saline solution with a motor driven 3431-E15 
Thomas glass/Teflon tissue homogeniser. The homogenate was submitted to 
preliminary cold centrifugation for 30 minutes at 10,000 rpm to remove gross 
tissue. The supernatant was decanted and subsequently subjected to ultra 
centrifugation at 105,000 g for 2 hours in a Beckman model L3-65 
Ultracentrifuge equipped with a type 40 rotor. This produced a multi-layered 
sediment and a clear reddish-yellow supernatant separated by an indistinct, cloudy 
boundary. The white lipid layer which floated to the top was removed and 
discarded, and the clear, reddish-yellow supernatant was carefully removed.  The 
supernatant served as the liver cytosol, which contained the hepatic regeneration 
stimulator substance and was used for infusion of the test animals. 
The steps in the preparation of liver cytosol are shown in figure 5.1. 
All preparatory steps were carried out at 40C or less. Approximately 140-160 
millilitres of supernatant was obtained.   
 




















































The animals in Groups 2 and 4 received a daily intraperitoneal injection of liver 
cytosol at a dose of 0.685 mg protein in 5 micro litres. 
INJECTION OF CYTOSOL  
E) 
The animals in Group 2 and 4 also received oral cyclosporine 4mg/kg twice daily. 
ORAL CYCLOSPORINE  
F) 
Five animals from each of the above groups were sacrificed at 24, 48, 72 and 96 
hours and at 1 and 2 weeks post-operatively.  The animals were exsanguinated 
under ether anaesthesia via a midline laparotomy and the liver remnant removed. 
SACRIFICE 
G) 
The blood specimens were used to measure the liver function tests (Biochemical). 
The liver remnants were used to measure the liver weight/body weight ratio and 
for histological examination to determine the mitotic indices.  
INVESTIGATIONS 
H) 
Blood was taken from the rats at the specified times of the experiment into 
heparin coated tubes. The blood was spun at 3000 rpm for 30 minutes to separate 
the plasma from the cells. The plasma was stored at -20C until the AST and ALT 
















: ALANINE TRANSAMINASE 
 
Reagents: 1) Sodium dehydrogenase NADH 
   Mw 709.4 
 2) Buffer 
   13.6gms of Potassium phosphate KH2PO4 
   3.3gms of Sodium hydroxide NAOH 
   Dissolve in distilled water and adjust the Ph to 7.4 
   Make up to one litre and store at 4OC 
 3) L-Alanine 
   Dissolve 7.6gms L-Alanine in 50ml Buffer. Dissolves while 
adjusting pH to 7.4 with Potassium hydroxide (KOH). Make 
up to 100ml with Buffer. Store at -20oC in 4.5ml aliquots. 
6) Lactate Dehydrogenase (LDH) 
   25mg/2.5ml 
7) Oxaloacetic Acid: 
  Dissolve 0.735gms Oxaloacetic Acid in 30ml Buffer. 
   Adjust pH to 7.4 and make up to 50ml 
   Store at -20oC in 5ml aliquots. 
Make up cocktail as follows: 
   36mgs Sodium dehydrogenase NADH 
   19ml Buffer 
   4.5ml L-Alanine 
   50ul LDH 
Method: 
   50ul Sample 
   650ul Cocktail 
   Stand at room temperature for 15minutes to equilibrate 
   50ul Oxaloacetic acid 
   Read absorbance at 340nm on spectrophotometer every 30 
seconds 
Calculation:    Total volume x delta absorbance  x dilution  I.U./litre 














: ASPARTIC TRANSAMINASE 
 
Reagents: 1) Sodium dehydrogenase NADH 
   Mw 709.4 
 2) Buffer 
   13.6gms of Potassium phosphate KH2PO4 
   3.3gms of Sodium hydroxide NAOH 
   Dissolve in distilled water and adjust the Ph to 7.4 
   Make up to one litre and store at 4OC 
 3) Aspartic Acid: 
   Dissolve 2.66gms Aspartic Acid in 50ml Buffer. Dissolves 
while adjusting pH to 7.4 with Potassium hydroxide (KOH). 
Make up to 100ml with Buffer. Store at -20oC in 4.5ml 
aliquots. 
4) Malate Dehydrogenase (MDA) 
   25mg/2.5ml 
5) Oxaloacetic Acid: 
  Dissolve 0.735gms Oxaloacetic Acid in 30ml Buffer. 
   Adjust pH to 7.4 and make up to 50ml 
   Store at -20oC in 5ml aliquots. 
Make up cocktail as follows: 
   36mgs Sodium dehydrogenase NADH 
   19ml Buffer 
   4.5ml Aspartic Acid 
   50ul MDA 
Method: 
   50ul Sample 
   650ul Cocktail 
   Stand at room temperature for 15minutes to equilibrate 
   50ul Oxaloacetic acid 
   Read absorbance at 340nm on spectrophotometer every 30 
seconds 
Calculation:    Total volume x delta absorbance  x dilution  I.U./litre 
















LIVER WEIGHT/BODY WEIGHT RATIO: 
The liver weight / body weight ratio was calculated by dividing the liver weight 
by the body weight at death. 
MITOTIC INDEX: 
The liver remnant was fixed in 10% formalin, dehydrated through 70%, 96% and 
100% alcohols. Then cleared in Xylol and impregnated with wax. This was done 
using a Leica TP 1020 Tissue processor. These tissue samples were then 
embedded in wax blocks and then cut into 1-2 micron sections and fixed onto 
microscopes slides at 56oC. 
 These sections were then dewaxed in xylol and rehydrated through alcohols 
(100% - 70%) and stained with Haematoxylin and Eosin 
The dividing cells were counted in 10 fields using a microscope and the results 
were given as cells per 10 fields. 
STATISTICAL ANALYSIS: 
The statistical analysis of results was done using the Shapiro-Wilk, the T-test, 




















LIVER FUNCTION TEST 
The changes in serum aspartate transferase (AST) levels are shown in 
Figure 6.1. The serum AST levels remained unchanged after sham 
operation (Group 3).  There was a significant increase in serum AST at 24 
hours after partial hepatectomy (P=0.019).  Thereafter, there was a gradual 
decrease in AST and a return to normal by 96 hours post-operatively.  
Serum AST levels were significantly higher at 24 hours in the animals 
subjected to partial hepatectomy and cytosol infusion (P=<0.001).  The 
serum AST levels in the animals subjected to sham operation with an 
injection of cyclosporine and cytosol (P=0.018) were also slightly higher 
than after sham operation only (Group 3). AST increases after PH because 













FIGURE 6.1:  CHANGES IN SERUM ASPARTATE 
TRANSFERASE (AST) AFTER STANDARD 2/3 PARTIAL 
















PH 624 194.4 20.4 62.2 79
PH+Cy+C 916.4 189 31.6 96.8 161
SHAM 51.6 45 43.9 45.2 75.4
SHAM+Cy+C 47.6 62 41.4 70 77.6
Mean 129





The changes in the serum alanine transferase (ALT) levels are shown in 
Figure 6.2.  The changes in serum ALT levels were similar to the changes 
in the serum AST. The serum ALT levels remained unchanged after sham 
operation (Group 3). Statistically, there was no significant increase in 
serum ALT at 24 hours after partial hepatectomy (P=1.000).  Thereafter 
there was a gradual decrease in ALT and a return to normal by 96 hours 
post-operatively.  Serum ALT levels were significantly higher at 24 hours 
in the animals subjected to partial hepatectomy and cytosol infusion 
(P=0.008).  The serum ALT levels in the animals subjected to sham 
operation with an injection of cyclosporine and cytosol (P=0.175) were 
also slightly higher than after sham operation only (Group 3). ALT 
increases after PH because of injury.  ALT is higher in the groups 



























FIGURE 6.2: CHANGES IN SERUM ALANINE TRANSFERASE (ALT) AFTER 
STANDARD 2/3 PARTIAL HEPATECTOMY AND ADMINISTRATION OF 
CYCLOSPORIN AND LIVER CYTOSOL.
PH 295.4 178.6 64 19.8 30.2 24
PH+Cy+C 464.2 222 99.2 46.6 38.2 43.3
SHAM 9.2 26.8 27 24.6 23.6 27.8
SHAM+Cy+C 14.4 46 37.6 23 27.4 46.8
Mean 37



























 MEAN MITOTIC INDICES OVER 10 FIELDS
PH 2 12 3 1 1 0
PH+Cy+C 0 14 8 5 0 0
SHAM 0 0 1 0 0 0
SHAM+Cy+C 0 0 0 0 0 0
Mean 0
0hrs 24hrs 48hrs 72hrs 96hrs 1wk 2wks
 
B) 
The changes in the mitotic indices in the four groups are shown in Figure 6.3.  
There was an increase in mitotic indices after partial hepatectomy at 24 hours and 
a further increase after 48 hours post-operatively. Thereafter the mitotic indices 
decreased to pre-operative levels by 2 weeks.  The mitotic indices in the animals 
subjected to PH + Cy + C (Group 2) were higher than in the animals in group 1.  
There were no mitotic figures seen in the animals subjected to sham operation. 
MITOTIC INDEX 
 
FIGURE 6.3:  CHANGES IN MITOTIC INDEX OF HEPATOCYTES IN REMNANT 
LIVER AFTER STANDARD 2/3 PARTIAL HEPATECTOMY AND ADMINISTRATION 











FIGURE 6.4 (a): Histological changes in the liver 24 hours after sham operation. 
Haematotoxylin and eosin (H&E) staining.  X20  
 
 













FIGURE 6.5 (a): Histological changes in the liver 24 hours after sham operation and 
administration of cytosol and cyclosporine. H&E X20   
 
 












FIGURE 6.6 (a):  Histological changes in the remnant liver 48 hours after standard 2/3 
partial hepatectomy.  H&E X20  
 
 












FIGURE 6.7 (a):  Histological changes in the remnant liver 2 weeks after standard 2/3 
partial hepatectomy.  H&E X20  
 
 












FIGURE 6.8 (a): Histological changes in the remnant liver 48 hours after standard 2/3 
partial hepatectomy and administration of cyclosporine and cytosol.  
H&E X20 
 












FIGURE 6.9 (a): Histological changes in the remnant liver 2 weeks after standard 2/3 







































PH 0 0.0206 0.03444 0.0336 0.0368 0.0362 0.04
PH+Cy+C 0 0.0217 0.03522 0.0364 0.034 0.0374 0.04
SHAM 0 0.04898 0.0416 0.0462 0.0366 0.0404 0.04
SHAM+Cy+C 0 0.0486 0.04608 0.0416 0.0424 0.0434 0.04
BLW 0.049
0hr 24hrs 48hrs 72hrs 96hrs 1wk 2wks
 
C) LIVER WEIGHT BODY WEIGHT RATIO 
The changes in the liver weight to body weight ratios in the animals studied are 
shown in Figure 6.10.  There was a significant reduction in the liver weight to 
body weight ratio at 24 hours after partial hepatectomy (P= <0.001).  This was 
compatible with a 2/3 partial hepatectomy.  Thereafter the liver weight to body 
weight ratios in the animals in groups 1 and 2 increased steadily, but had still not 
reached pre-operative levels by 2 weeks after partial hepatectomy.  Interestingly, 
the liver weight to body weight ratios in the animals subjected to sham operation 
decreased slightly over the 2 weeks.  Treatment with liver cytosol or cyclosporine 
did not influence the liver weight to body weight ratio. 
 
FIGURE 6.10:  CHANGES IN LIVER WEIGHT BODY WEIGHT RATIO IN 












In summary, AST and ALT unchanged after sham operation. AST and ALT increase 
after PH represents injury. The increase in AST and ALT in groups 2 and 4 related to 
liver enzymes in cytosol. 
 
There were no mitotic figures seen in the animals subjected to sham operations. Increase 
mitotic index after PH reflect regeneration. Further increase in mitotic indices after PH + 
C + Cy represent increased regeneration over stimulus of PH related to hepatotrophic 
factors in cytosol and hepatotrophic effect of cyclosporine. 
 
The liver weight/body weight (LW/BW) ratios increased after PH but had returned to 


















Living donor liver transplantation is now performed routinely in most major centres 
throughout the world 1, with 1 and 5years survival rates between 85 and 75% respectively 
2. The improvement in the knowledge of liver anatomy, surgical technique, use of 
immunosuppressant drugs and the management of haemodynamics has resulted in an 
increased number of transplant centres and an increasing number of living donor liver 
transplantations. However, the regenerative response in the remnant liver in the donor 
and in the transplanted liver in the recipient has been studied previously.89, 90 It has been 
noted that the restoration of liver mass in the donor takes longer than in the recipient, and 
that the liver volume does not return to pre-operative size by 12 months after the surgery.  
Several factors in the recipient may account for the discrepancy in the regenerative 
response compared to the donor. 
 
Firstly, the recipient has high levels of circulating hepatotrophic factors because of the 
liver disease.  Secondly, the recipient also receives cyclosporine, which is known to be 
hepatotrophic in the post transplant period. In contrast, the donor does not have any 
circulating hepatotrophic factors because of the normal liver preoperatively, and secondly 
does not receive cyclosporine post operatively. 
 
Long Evans rats were subjected to either standard 2/3 partial hepatectomy (PH) or sham 
operation (SH) and were randomly allocated to the following treatment groups. 
Group 1: partial hepatectomy (PH) 
Group 2: partial hepatectomy and administration of cyclosporine and liver cytosol 
(PH + C + Cy) 
Group 3: sham operation (SH) 
Group 4: sham operation and administration of cyclosporine and liver cytosol (SH + 
Cy +C). 
The AST and ALT levels were determined. The mitotic indices were obtained by 
counting the dividing cells using microscope and the results were given as cells per 10 
fields. The liver weight/body weight ratio was calculated by dividing the liver weight by 












In this study we noted that the increase in AST and ALT in groups 2 and 4 are related to 
liver enzymes in cytosol. Moreover, liver mass had not yet returned to pre-operative 
levels by 2 weeks after partial hepatectomy in rats. The peak regenerative response, using 
DNA synthesis and mitotic index as markers of liver regeneration, is known to occur 
during the first 24 to 48 hours after partial hepatectomy. Most studies have been limited 
to the first post-operative week and the above markers have usually returned to normal by 
then. Restoration of liver mass is generally not used as an endpoint of liver regeneration. 
 
Liver mass is obviously a very crude estimation and is influenced by water and fat 
content. These factors were not taken into consideration in these studies. However, the 
histological evaluation of the livers did not show any evidence of increased fat in the 
livers. In the clinical studies of liver transplant donors and recipients, liver mass has been 
estimated using CT scan calculations, 80 which are also relatively inaccurate. 
 
The recipient presumably has high levels of hepatic growth factors in the circulation as a 
result of the liver disease.  To simulate this, we infused liver cytosol from regenerating 
livers into animals after partial hepatectomy or sham operation.  The liver cytosol did 
appear to modify the regenerative response after partial hepatectomy as indicated by the 
increased mitotic index. However, liver cytosol did not initiate a regenerative response 
after sham operation.  Furthermore, liver cytosol did not modify the restoration of liver 
mass after partial hepatectomy. 
 
Cyclosporine has also been shown to potentiate the regenerative response after partial 
hepatectomy.84-87 In this study the animals receiving cyclosporine after partial 
hepatectomy had a greater mitotic index level compared to after partial hepatectomy.  
However, the restoration of liver mass was not modified by the addition of cyclosporine. 
 
In summary, therefore, liver mass in this study was not restored by 2 weeks after partial 
hepatectomy even though the mitotic index had returned to normal after 48 to 72 hours. 
Hepatotrophic factors and cyclosporine, which are thought to be responsible for the more 
rapid growth of the liver in the recipient compared to the donor in living donor liver 












LEGENDS:  PHOTOMICROGRAPHS 
FIGURE 6.4 (a): Histological changes in the liver 24 hours after sham operation. 
Haematotoxylin and eosin (H&E) staining.  X20. 
(b) Close-up of the boxed area in (a).  No mitosis. H&E X40. 
FIGURE 6.5 (a): Histological changes in the liver 24 hours after sham operation and 
administration of cytosol and cyclosporine. H&E X20. 
(b) Close-up of the boxed area in (a).  No mitosis. H&E X40. 
FIGURE 6.6 (a): Histological changes in the remnant liver 48 hours after standard 
2/3 partial hepatectomy.  H&E X20. 
(b) Close-up of the boxed area in (a) showing mitosis (arrow). H&E 
X40. 
FIGURE 6.7 (a): Histological changes in the remnant liver 2 weeks after standard 
2/3 partial hepatectomy.  H&E X20. 
(b) Close-up of the boxed area in (a). No mitosis. H&E X40. 
FIGURE 6.8 (a): Histological changes in the remnant liver 48 hours after standard 
2/3 partial hepatectomy and administration of cyclosporine and 
cytosol.  H&E X20. 
(b) Close-up of the boxed area in (a) showing mitosis (arrow). H&E 
X40. 
FIGURE 6.9 (a): Histological changes in the remnant liver 2 weeks after standard 
2/3 partial hepatectomy and administration of cyclosporine and 
cytosol.  H&E X20. 
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STATISTICAL ANALYSIS OF RESULTS 
 
Though the sample size is small, the Shapiro-Wilk test revealed that the values are 
normally distributed. 
 
The t-test shows no significant difference between PH and PH + C + Cy. (p=0.2448) 
 
One-way analysis of variants was applied to test the significant difference between the 
four groups. This revealed an overall significant difference between the groups. 
(p=0.0001) 
 
The Bonferroni for selected comparison was used to show which groups are significant. 
There is significant difference between: 
• PH and Sham                           (p=<0.019) 
• PH and Sham+ C+ Cy                (p=<0.001) 
• PH + C + Cy and Sham            (p=<0.001) 
 
 
 Oneway ast_ul24        procedure, tab bon 
 
                 |         Summary of AST_UL24 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |         624   312.63717           5 
 PH + Cy + Cytos |       916.4   416.60869           5 
            Sham |        51.6   17.472836           5 
Sham + Cy + Cyto |        47.6   12.895736           5 
-----------------+------------------------------------ 
           Total |       409.9   452.89779          20 
 
                     Comparison of AST_UL24 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy +Cytos         Sham 
---------+--------------------------------- 
PH + Cs |      292.4 
         |      0.571 
         | 
    Sham |     -572.4      -864.8 
         |   P = 0.019      0.000 
         | 
Sham + C |     -576.4      -868.8              -4 

















 oneway ast_ul48        procedure, tab bon 
 
                 |         Summary of AST_UL48 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       296.2   133.49607           5 
 PH + Cy + Cytos |         486   133.33792           5 
            Sham |        43.8   15.896541           5 
Sham + Cy + Cyto |        76.2   18.660118           5 
-----------------+------------------------------------ 
           Total |      225.55   203.34375          20 
 
 
                     Comparison of AST_UL48 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cs  |      189.8 
         |      0.037 
         | 
    Sham |     -252.4     -442.2 
         |      0.004      0.000 
         | 
Sham + C |       -220     -409.8               32.4 
         |      0.013      0.000              1.000 
 
Oneway ast_ul72        procedure, tab bon 
 
                 |         Summary of AST_UL72 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       194.4   87.503143           5 
 PH + Cy + Cytos |       189.8  42.938328           5 
            Sham |        47.8   4.0865633           5 
Sham + Cy + Cyto |          62   20.518285           5 
-----------------+------------------------------------ 
           Total |       123.5   84.114271          20 
 
 
                     Comparison of AST_UL72 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |       -4.6 
         |      1.000 
         | 
    Sham |     -146.6       -142 
         |      0.002      0.002 
         | 
Sham + C |     -132.4     -127.8               14.2 














 Oneway ast_ul96        procedure, tab bon 
 
                 |         Summary of AST_UL96 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |        32.4   8.8487287           5 
 PH + Cy + Cytos |        64.8   9.1487704           5 
            Sham |        29.6   14.909728           5 
Sham + Cy + Cyto |        41.4   4.2190046           5 
-----------------+------------------------------------ 
           Total |       42.05   16.919235          20 
 
 
                     Comparison of AST_UL96 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |       32.4 
         |      0.001 
         | 
    Sham |       -2.8      -35.2 
         |      1.000      0.000 
         | 
Sham + C |          9      -23.4               11.8 
         |      1.000      0.012               0.487 
 
 Oneway ast_ul7days     procedure, tab bon 
 
                 |       Summary of AST_UL7days 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |        62.2   8.5848704           5 
 PH + Cy + Cytos |        96.8    45.72964           5 
            Sham |        45.2   6.0580525           5 
Sham + Cy + Cyto |          70   22.638463           5 
-----------------+------------------------------------ 
           Total |       68.55   30.594934          20 
 
                    Comparison of AST_UL7days by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |       34.6 
         |      0.312 
         | 
    Sham |        -17      -51.6 
         |      1.000      0.039 
         | 
Sham + C |        7.8      -26.8               24.8 




 Oneway ast_ul14days    procedure, tab bon 
 
                 |       Summary of AST_UL14days 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |          79   16.807736           5 
 PH + Cy + Cytos |         161   59.556696           3 
            Sham |        75.4   10.830512           5 
Sham + Cy + Cyto |        77.6    11.28273           5 
-----------------+------------------------------------ 













                   Comparison of AST_UL14days by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |         82 
         |      0.004 
         | 
    Sham |       -3.6      -85.6 
         |      1.000      0.003 
         | 
Sham + C |       -1.4      -83.4        2.2 
         |      1.000      0.003      1.000 
 
Oneway alt_ul24        procedure, tab bon 
 
                 |         Summary of ALT_UL24 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       295.4   97.715403           5 
 PH + Cy + Cytos |       464.2   357.73901           5 
            Sham |         9.2   1.7888544           5 
Sham + Cy + Cyto |        14.4   6.7305275           5 
-----------------+------------------------------------ 
           Total |       195.8   261.44509          20 
 
                     Comparison of ALT_UL24 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |      168.8 
         |      1.000 
         | 
    Sham |     -286.2       -455 
         |      0.160      0.008 
         | 
Sham + C |       -281     -449.8               5.2 
         |      0.175      0.009               1.000 
 
 
 Oneway alt_ul48        procedure, tab bon 
 
                 |         Summary of ALT_UL48 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       178.6   82.829946           5 
 PH + Cy + Cytos |         222   69.188149           5 
            Sham |        26.8   10.894953           5 
Sham + Cy + Cyto |          46   21.702534           5 
-----------------+------------------------------------ 
           Total |      118.35   99.709196          20 
 
                     Comparison of ALT_UL48 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |       43.4 
         |      1.000 
         | 
    Sham |     -151.8     -195.2 
         |      0.003      0.000 
         | 
Sham + C |     -132.6       -176               19.2 













 Oneway alt_ul72        procedure, tab bon 
 
                 |         Summary of ALT_UL72 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |          64   30.659419           5 
 PH + Cy + Cytos |        99.2   28.943048           5 
            Sham |          27    9.486833           5 
Sham + Cy + Cyto |        37.6   5.4129474           5 
-----------------+------------------------------------ 
           Total |       56.95   34.882472          20 
 
 
                     Comparison of ALT_UL72 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |       35.2 
         |      0.127 
         | 
    Sham |        -37      -72.2 
         |      0.097      0.000 
         | 
Sham + C |      -26.4      -61.6               10.6 
         |      0.440      0.002                1.000 
 
 
 Oneway alt_ul96        procedure, tab bon 
 
                 |         Summary of ALT_UL96 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |        19.8   4.6043458           5 
 PH + Cy + Cytos |        46.6   11.193748           5 
            Sham |        24.6   9.9146356           5 
Sham + Cy + Cyto |          23  2.7386128           5 
-----------------+------------------------------------ 
           Total |        28.5   13.084744          20 
 
                     Comparison of ALT_UL96 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |       26.8 
         |      0.000 
         | 
    Sham |        4.8        -22 
         |      1.000      0.003 
         | 
Sham + C |        3.2      -23.6               -1.6 
         |      1.000      0.001                1.000 
 
 Oneway alt_ul7days     procedure, tab bon 
 
                 |       Summary of ALT_UL7days 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |        30.2   8.1363382           5 
 PH + Cy + Cytos |        38.2   6.8702256           5 
            Sham |        23.6   7.8930349           5 
Sham + Cy + Cyto |        27.4   7.5033326           5 
-----------------+------------------------------------ 












                    Comparison of ALT_UL7days by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |          8 
         |      0.697 
         | 
    Sham |       -6.6      -14.6 
         |      1.000      0.048 
         | 
Sham + C |       -2.8      -10.8                3.8 
         |      1.000      0.237                1.000 
 
 Oneway alt_ul14days    procedure, tab bon 
 
                 |       Summary of ALT_UL14days 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |          24   3.5355339           5 
 PH + Cy + Cytos |   43.333333   3.7859389           3 
            Sham |        27.8   2.8635642           5 
Sham + Cy + Cyto |        46.8    12.00833           5 
-----------------+------------------------------------ 
           Total |   34.611111   12.015377          18 
 
                   Comparison of ALT_UL14days by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |    19.3333 
         |      0.012 
         | 
    Sham |        3.8    -15.5333 
         |      1.000      0.054  
         | 
Sham + C |       22.8     3.46667                19 
         |      0.001      1.000                0.005 
 
 Oneway lwr_ul24        procedure, tab bon 
 
                 |         Summary of LWR_UL24 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       .0206   .00162173           5 
 PH + Cy + Cytos |       .0217   .00257294           5 
            Sham |      .04898   .00209809           5 
Sham + Cy + Cyto |      .04856   .00372062           5 
-----------------+------------------------------------ 
           Total |      .03496   .01437792          20 
 
                     Comparison of LWR_UL24 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |      .0011 
         |      1.000 
         | 
    Sham |     .02838     .02728 
         |      0.000      0.000 
         | 
Sham + C |     .02796     .02686              -.00042 











 Oneway lwr_ul48        procedure, tab bon 
 
                 |         Summary of LWR_UL48 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |      .03444   .00286496           5 
 PH + Cy + Cytos |      .03522   .00108028           5 
            Sham |       .0416   .00294024           5 
Sham + Cy + Cyto |      .04608   .00483032           5 
-----------------+------------------------------------ 
           Total |     .039335   .00572624          20 
 
                     Comparison of LWR_UL48 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |     .00078 
         |      1.000 
         | 
    Sham |     .00716     .00638 
         |      0.017      0.038 
         | 
Sham + C |     .01164     .01086              .00448 
         |      0.000      0.000              0.256 
 
 Oneway lwr_ul72        procedure, tab bon 
 
                 |         Summary of LWR_UL72 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       .0356   .00879204           5 
 PH + Cy + Cytos |       .0364   .00270185           5 
            Sham |       .0462   .00535724           5 
Sham + Cy + Cyto |       .0416   .00439318           5 
-----------------+------------------------------------ 
           Total |      .03995    .0068708          20 
 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |      .0008 
         |      1.000 
         | 
    Sham |      .0106      .0098 
         |      0.061      0.096 
         | 
Sham + C |       .006      .0052              -.0046 




 Oneway lwr_ul96        procedure, tab bon 
 
                 |         Summary of LWR_UL96 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       .0368   .00228035           5 
 PH + Cy + Cytos |        .034   .00223607           5 
            Sham |       .0366   .00151657           5 
Sham + Cy + Cyto |       .0424   .00391152           5 
-----------------+------------------------------------ 













                     Comparison of LWR_UL96 by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |     -.0028 
         |      0.675 
         | 
    Sham |     -.0002      .0026 
         |      1.000      0.831 
         | 
Sham + C |      .0056      .0084               .0058 
         |      0.024      0.001                0.019 
 
 Oneway lwr_ul7days     procedure, tab bon 
 
                 |       Summary of LWR_UL7days 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |       .0362   .00164317           5 
 PH + Cy + Cytos |       .0374   .00250998           5 
            Sham |       .0404   .00207364           5 
Sham + Cy + Cyto |       .0434   .00207364           5 
-----------------+------------------------------------ 
           Total |      .03935   .00345307          20 
 
                    Comparison of LWR_UL7days by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |      .0012 
         |      1.000 
         | 
    Sham |      .0042       .003 
         |      0.036      0.228 
         | 
Sham + C |      .0072       .006               .003 
         |      0.000      0.002              0.228 
 
 
 Oneway lwr_ul14days    procedure, tab bon 
 
                 |       Summary of LWR_UL14days 
       Procedure |        Mean   Std. Dev.       Freq. 
-----------------+------------------------------------ 
              PH |         .04   .00291548           5 
 PH + Cy + Cytos |   .04033333   .00585947           3 
            Sham |       .0402   .00192354           5 
Sham + Cy + Cyto |       .0432   .00432435           5 
-----------------+------------------------------------ 
           Total |        .041   .00364611          18 
 
 
                   Comparison of LWR_UL14days by Procedure 
                                (Bonferroni) 
Row Mean-| 
Col Mean |         PH   PH + Cy + Cytos        Sham 
---------+--------------------------------- 
PH + Cy  |    .000333 
         |      1.000 
         | 
    Sham |      .0002   -.000133 
         |      1.000      1.000 
         | 
Sham + C |      .0032    .002867               .003 
         |      1.000      1.000              1.000 
